Half of our hypertensive cohort were on a combination therapy (i.e., >1 anti-hypertensive drug) and 90% used either an ARB, ACE-I, or CCB, which may have contributed to the similar cognitive health between our HTN and non-HTN groups. Here, ACE is linked to hypertensive disorder.